S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:RLMD

Relmada Therapeutics Competitors

$34.23
+1.01 (+3.04 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.56
Now: $34.23
$34.32
50-Day Range
$31.52
MA: $35.16
$38.46
52-Week Range
$23.25
Now: $34.23
$54.00
Volume81,053 shs
Average Volume79,411 shs
Market Capitalization$555.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53

Competitors

Relmada Therapeutics (NASDAQ:RLMD) Vs. PBH, AMTI, DRNA, CYRX, MYOV, and KURA

Should you be buying RLMD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Relmada Therapeutics, including Prestige Consumer Healthcare (PBH), Applied Molecular Transport (AMTI), Dicerna Pharmaceuticals (DRNA), Cryoport (CYRX), Myovant Sciences (MYOV), and Kura Oncology (KURA).

Relmada Therapeutics (NASDAQ:RLMD) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Prestige Consumer Healthcare04302.43

Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 85.02%. Prestige Consumer Healthcare has a consensus target price of $80.1667, suggesting a potential upside of 84.16%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Prestige Consumer Healthcare.

Profitability

This table compares Relmada Therapeutics and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Prestige Consumer Healthcare17.03%13.76%4.80%

Earnings and Valuation

This table compares Relmada Therapeutics and Prestige Consumer Healthcare's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85
Prestige Consumer Healthcare$963.01 million2.25$142.28 million$2.9614.71

Prestige Consumer Healthcare has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Insider and Institutional Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Relmada Therapeutics on 8 of the 12 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Applied Molecular Transport (NASDAQ:AMTI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Applied Molecular Transport, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Applied Molecular Transport00303.00

Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 85.02%. Applied Molecular Transport has a consensus target price of $48.6667, suggesting a potential downside of 19.13%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Applied Molecular Transport.

Profitability

This table compares Relmada Therapeutics and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Applied Molecular TransportN/AN/AN/A

Earnings and Valuation

This table compares Relmada Therapeutics and Applied Molecular Transport's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Insider and Institutional Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Applied Molecular Transport beats Relmada Therapeutics on 4 of the 7 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Dicerna Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Dicerna Pharmaceuticals00703.00

Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 85.02%. Dicerna Pharmaceuticals has a consensus target price of $37.4286, suggesting a potential upside of 36.60%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Dicerna Pharmaceuticals.

Profitability

This table compares Relmada Therapeutics and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

Earnings and Valuation

This table compares Relmada Therapeutics and Dicerna Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85
Dicerna Pharmaceuticals$23.90 million87.50$-120,460,000.00($1.76)-15.57

Relmada Therapeutics has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Dicerna Pharmaceuticals beats Relmada Therapeutics on 8 of the 12 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Cryoport (NASDAQ:CYRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Relmada Therapeutics and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Cryoport-55.87%-17.68%-11.32%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Cryoport, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Cryoport00603.00

Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 85.02%. Cryoport has a consensus target price of $70.00, suggesting a potential upside of 33.33%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Cryoport.

Insider and Institutional Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Relmada Therapeutics and Cryoport's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85
Cryoport$33.94 million61.35$-18,330,000.00($0.55)-95.45

Relmada Therapeutics has higher earnings, but lower revenue than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Summary

Cryoport beats Relmada Therapeutics on 9 of the 12 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Myovant Sciences and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
Relmada TherapeuticsN/A-32.03%-31.41%

Analyst Recommendations

This is a breakdown of current recommendations for Myovant Sciences and Relmada Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
Relmada Therapeutics01202.67

Myovant Sciences currently has a consensus price target of $31.1667, suggesting a potential upside of 42.38%. Relmada Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 85.02%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Myovant Sciences.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Myovant Sciences and Relmada Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.50
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Myovant Sciences has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Relmada Therapeutics beats Myovant Sciences on 6 of the 10 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Kura Oncology and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kura OncologyN/A-30.96%-28.02%
Relmada TherapeuticsN/A-32.03%-31.41%

Analyst Recommendations

This is a breakdown of current recommendations for Kura Oncology and Relmada Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kura Oncology011002.91
Relmada Therapeutics01202.67

Kura Oncology currently has a consensus price target of $39.5455, suggesting a potential upside of 32.97%. Relmada Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 85.02%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Kura Oncology.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are held by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are held by institutional investors. 11.0% of Kura Oncology shares are held by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Kura Oncology and Relmada Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.70
Relmada TherapeuticsN/AN/AN/A($2.16)-15.85

Kura Oncology is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Kura Oncology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Kura Oncology beats Relmada Therapeutics on 8 of the 10 factors compared between the two stocks.


Relmada Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.53+2.5%$2.17 billion$963.01 million13.52
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$60.18+0.9%$2.10 billionN/A0.00Upcoming Earnings
Gap Down
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.40+1.2%$2.09 billion$23.90 million-17.02Analyst Report
Analyst Revision
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.50+0.8%$2.08 billion$33.94 million-90.52Earnings Announcement
Analyst Report
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$21.89+4.1%$1.99 billionN/A-7.79Gap Up
Kura Oncology logo
KURA
Kura Oncology
1.6$29.74+4.3%$1.97 billionN/A-18.25Analyst Report
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.5$26.29+2.2%$1.88 billion$410,000.00-5.72Insider Selling
Gap Up
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$116.28+3.6%$1.86 billionN/A-10.50Analyst Report
Analyst Revision
News Coverage
Gap Up
HRMY
Harmony Biosciences
1.4$32.40+1.9%$1.84 billionN/A0.00Analyst Downgrade
News Coverage
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.6$32.75+5.7%$1.82 billionN/A0.00Upcoming Earnings
Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.2$54.01+5.3%$1.81 billionN/A-30.01Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.95+6.6%$1.79 billion$82.27 million-21.83Gap Up
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
2.0$25.81+4.6%$1.78 billion$103.54 million-19.41Earnings Announcement
Analyst Report
Insider Selling
News Coverage
Gap Down
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$59.89+2.7%$1.77 billion$970,000.000.00Upcoming Earnings
Analyst Report
Increase in Short Interest
News Coverage
Gap Down
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.06+5.0%$1.74 billion$34.51 million-16.29Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$42.33+2.9%$1.72 billionN/A0.00Upcoming Earnings
Gap Down
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$13.09+2.4%$1.67 billion$320,000.00-8.90News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.11+1.2%$1.63 billion$428.41 million14.65Insider Buying
ORGO
Organogenesis
1.0$15.09+3.3%$1.63 billion$260.98 million-251.50Gap Up
Endo International logo
ENDP
Endo International
1.1$6.99+1.4%$1.61 billion$2.91 billion-10.28Analyst Report
Analyst Revision
News Coverage
Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.49+3.1%$1.60 billion$145.97 million-7.08Analyst Upgrade
Shattuck Labs logo
STTK
Shattuck Labs
1.3$38.09+6.3%$1.59 billionN/A0.00Upcoming Earnings
Gap Down
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$35.10+0.4%$1.57 billionN/A0.00News Coverage
ADCT
ADC Therapeutics
1.6$22.75+4.4%$1.57 billion$2.34 million-9.64Upcoming Earnings
Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$31.25+1.8%$1.57 billionN/A-3.39Gap Up
Kronos Bio logo
KRON
Kronos Bio
1.8$27.87+5.2%$1.56 billionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$22.37+2.1%$1.52 billionN/A-9.44
Zymeworks logo
ZYME
Zymeworks
1.8$32.94+3.0%$1.52 billion$29.54 million-8.74Analyst Report
Increase in Short Interest
Gap Up
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$4.95+2.4%$1.48 billion$1.63 billion12.07Analyst Revision
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$41.08+3.6%$1.48 billionN/A0.00Upcoming Earnings
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.4$26.01+7.4%$1.46 billion$64.19 million-8.31Analyst Report
Gap Up
OLMA
Olema Pharmaceuticals
1.7$37.66+3.3%$1.45 billionN/A0.00
uniQure logo
QURE
uniQure
1.9$32.48+1.4%$1.45 billion$7.28 million-8.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.2$37.76+0.6%$1.44 billion$14.87 million-14.09Upcoming Earnings
Analyst Downgrade
High Trading Volume
Unusual Options Activity
News Coverage
NKTX
Nkarta
1.8$43.71+1.7%$1.42 billionN/A0.00Upcoming Earnings
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.68+1.1%$1.42 billion$7.51 million-6.13
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.4$18.51+6.4%$1.40 billion$4.23 million-10.34Upcoming Earnings
News Coverage
Gap Up
Cytokinetics logo
CYTK
Cytokinetics
1.7$19.68+5.6%$1.40 billion$26.87 million-10.30Analyst Downgrade
High Trading Volume
Gap Up
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.8$36.42+9.7%$1.39 billionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$26.99+2.4%$1.38 billion$175.34 million-15.88Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.00+0.0%$1.35 billion$6.20 million-13.60Upcoming Earnings
News Coverage
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.6$45.89+3.7%$1.33 billionN/A-3.28Insider Selling
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.6$25.15+4.0%$1.32 billion$392.76 million10.43Analyst Downgrade
Gap Up
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$32.64+1.8%$1.32 billionN/A-10.99Earnings Announcement
High Trading Volume
Decrease in Short Interest
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.7$25.98+1.8%$1.30 billionN/A-8.55Earnings Announcement
Analyst Report
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.6$18.41+1.7%$1.27 billion$42.12 million-13.64Earnings Announcement
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$37.38+11.5%$1.26 billion$28.95 million-53.40Analyst Downgrade
Insider Selling
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$26.31+1.4%$1.26 billionN/A-9.71
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$19.45+3.5%$1.25 billion$73.41 million-4.11Analyst Report
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$58.62+5.7%$1.18 billionN/A0.00Upcoming Earnings
Insider Selling
News Coverage
Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.